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Abstract
Apolipoprotein  E  (apoE)  is  a  multifunctional  circulating  34-kDa  protein, 
whose  gene  encodes  single  nucleotide  polymorphisms  linked  to  several 
neurodegenerative  diseases.    Here,  we  evaluate  whether  synthetic  RNA/DNA 
oligonucleotides  (chimeraplasts)  can  convert  a  dysfunctional  gene, APOE4 (C→T, 
Cys112Arg),  a  risk  factor  for  Alzheimer’s  disease  and  other  neurological 
disordersatherosclerosis,  into  wild-type  APOE3.    In  preliminary  experiments,  we 
treated recombinant Chinese hamster ovary (CHO) cells stably secreting apoE4 and 
lymphocytes from a patient homozygous for the ε4 allele with a 68-mer apoE4-to-
apoE3  chimeraplast, complexed to the cationic delivery reagent, polyethylenimine.  
Genotypes were analysed after 48 h by routine polymerase chain reaction-restriction 
fragment  length  polymorphism  (PCR-RFLP)  and  by  genomic  sequencing.    Clear 
conversions of APOE4 to APOE3 were detected using either technique, although high 
concentrations of chimeraplast were needed (≥800 nM).  Spiking experiments of PCR 
reactions or CHO-K1 cells with the chimeraplast confirmed that the repair was not 
artefactual.  However, when treated recombinant CHO cells were passaged for ten 
days and then subcloned, no conversion could be detected when >90 clones were 
analysed by locus-specific PCR-RFLP.  We conclude that the apparent efficient repair 
of the APOE4 gene in CHO cells or lymphocytes 48 h post-treatment is unstable, 
possibly because the high levels of chimeraplast and polycationethylenimine needed 
to induce nucleotide substitution is cytotoxic. 
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synthetic oligonucleotidesIntroduction
Apolipoprotein E (apoE) is a circulating 34-kDa polymorphic protein that in 
plasma functions as an acceptor of cellular cholesterol and as a ligand to mediate 
hepatic clearance of lipoprotein remnant particles (Mahley and Ji, 1999; Mahley et al., 
2000).  In helps redistribute cholesterol between cells and acts as a ligand for several 
cell-surface  receptors.    In  plasma,  and  in  cerebrospinal  fluid,  about  half  of  all 
apolipoproteins are apoE (Koch et al., 2001), most being synthesized by astrocytes 
and  microglia  (Strittmatter  and  Bova  Hill,  2002).    ApoE    where  it  is  a  major 
apolipoprotein1,  fulfills  several  functions,  all  mediated  via  receptor-dependent 
pathways,  including  maintenance  of  cholesterol  homeostasis  and  local  cholesterol 
redistribution  within  tissue  undergoing  repair  or  re-modelling,  developmental 
processes  and  synapse  formation  (Beffert  et  al.,  1998;  Beffert  et  al.,  2004).    it 
functions  as  an  acceptor  of  cellular  cholesterol  and  also  clears  lipoproteins  via 
receptor-dependent  pathways2,3.    The  two  common  isoforms  of  apoE  arise  from 
nonsynonymous  coding  single  nucleotide  polymorphisms  (SNP)  of  the  wild-type 
APOE3 gene.  The rarest allele ε2 (8% frequency, C→T, Arg158Cys) causes recessive 
hypercholesterolaemia2,  while  the  ε4  allele  (15%  frequency;  C→T,  Cys112Arg) 
produces a dominant hypercholesterolaemia and is a strong risk factor for restenosis4
and  smoking-related  heart  disease5.    ApoE  alleles  are  also  strongly  linked  to 
Alzheimer’s  disease  (AD)  and  several  chronic  neurodegenerative  diseases;  the  ε4
allele imparts risk, while ε2 appears protective6,7. the rarest allele ε2 (8% frequency, 
C→T, Arg158Cys) appears protective (Gasparini et al., 1998; Saunders, 2000).   The 
mechanism(s)  underlying  these  associations  is  unknown,  but  may  reflect  isoform 
differences  in  intracellular  apoE  trafficking  or  in  receptor-dependent  cell  signalling 
pathways3,8,9. (Mahley et al., 2000; Strittmatter and Bova Hill, 2002; Sacre et al., 2003)
Recently, synthetic RNA/DNA oligonucleotides have been used to repair point 
mutations in episomal and genomic DNA10,11. (Richardson et al., 2002; Rice et al., 
2001).    These  reagents,  often  termed  chimeraplasts,  are  double-stranded  hairpin-
capped  molecules  which  are  designed  to  bind  specifically  to  the  defective  DNA, 
enabling the cell's own repair machinery to recognize and correct the faulty DNA.  
Several groups have reported promising results using chimeraplasts (Richardson et al., 2002; Rice et al., 2001; Cole-Strauss et al., 1996; Kren et al., 1998; Alexeev et al., 
2000;  Bertoni  and  Rando,  2002),10-15,  including  our  own  which  has  successfully 
converted the dysfunctional APOE2 gene to wild-type APOE3, both in vitro and in 
vivo16 (Tagalakis et al., 2001).  Here, we apply chimeraplasty to recombinant Chinese 
hamster ovary (CHO) cells expressing human apoE4, and also to cultured lymphocytes 
from a patient homozygous for the ε4 allele, in an attempt to convert mutant APOE4 to 
wild-type APOE3.  Despite early encouraging results in short-term studies, we were 
unable to achieve consistent and reproducible conversions in the long term.
Materials and Methods
Cell culture
The cloned CHO cell line expressing human apoE4 that was used in these studies was 
produced  by  the  method  previously  described  for  CHO-E2  cells  (Tagalakis  et  al., 
2001).    These  recombinant  cells  were  cultured in  Iscove’s  modified  Dulbecco’s 
medium with 10% dialyzed FBS (fetal bovine serum; Sigma), supplemented with 2 
mM glutaMAX and 1% non-essential aminoacids (Life Technologies).  Lymphocytes 
were isolated from the heparinized-blood of a patient homozygous for the ε4 allele 
and immortalized with Epstein-Barr virus (Negri et al., 1991).  These transformed 
cells were grown as suspension cultures in RPMI 1640 medium, supplemented with 
10% FBS and 2 mM L-glutamine. 
Chimeraplasty and transfections
The RNA/DNA oligonucleotides were synthesized commercially by MWG-Biotech 
(Ebersberg, Germany) to designs dictated by the target DNA (Fig. 1A).  One strand of 
the self-associating duplex, termed the 'targeting strand (Gamper et al., 2000), had ten 
complementary  2'-O-methyl  RNA  residues  flanking  each side  of  the  5-base-DNA 
stretch.  The protected RNA bases resist RNase H-mediated degradation, while four 
T-residues in each loop and a 5 bp GC clamp ensured that they self-associated into a 
double-hairpin.    The  other  'correcting  strand'  was  all  DNA  and,  except  for  the 
intended base mismatch, was complementary to the genomic DNA target.  Cells were 
seeded  into 6-well  plates  (2  ×  105 cells/well)  24  h  prior  to  transfections.  
Chimeraplasts  (400-1000  nM)  were  pre-incubated  for  10  min  with  linear  22-kDa polyethyleneimine  (PEI)  (ExGen  500;  TCS  Biologicals  Ltd.),  at  different 
amine:phosphate molar ratios (5:1 to 9:1) and with the addition of 150 mM NaCl.  
The complexes (50 µl) were then added to each well of cells growing in 0.5 ml of 
serum-containing medium.  After 4-6 h, monolayers were washed with phosphate-
buffered saline and incubated with 2 ml of fresh medium for 48 h prior to harvesting 
the cells and extracting genomic DNA.  In the long-term experiments, we continued to 
passage and culture cells for 10 days before isolating clones by limiting dilution and 
ring cloning. 
ApoE genotyping and DNA sequencing
Genomic DNA (DNeasy kit; Qiagen) was extracted from cells for routine PCR-RFLP 
genotyping (Hixson and Vernier, 1990), amplifying a 227 bp product by 36 cycles (94 
°C  for  30  sec  and  68  °C  for  30  sec)  with  the  primer  pair,  5’-
TCCAAGGAGCTGCAGGCGGCGCA-3’  (sense)  and  5’-
ACAGAATTCGCCCCGGCCTGGTACACTGCCA-3’ (antisense) and separating the 
HhaI  digested  fragments  on  20%  Tris-buffered  EDTA-polyacrylamide  gels 
(Invitrogen).  Each genotype gave a specific combination of HhaI fragment sizes: 
apoE2, 91 and 83 bp; apoE3, 91 and 48 bp; and apoE4, 72 and 48 bp (Fig. 1b).  A 
locus-specific PCR was also devised to avoid the appearance of ambiguous fragments, 
which often result from routine PCR-RFLP analyses involving the apoE4 genotype 
(Wu et al., 2000).  This involved 36 cycles of PCR (94 °C for 30 sec and 68 °C for 30 
sec)  with  the  primer  pair,  5’-AGGCCCGGCTGGGCGTGGA-3’  (sense)  and  5’-
TGGGAGGCGAGACGCACCCG-3’  (antisense)  and  was  designed  to  amplify  a 
region around the E4/E3 locus, whilst abolishing two HhaI restriction sites.  The final 
118 bp product contains only one HhaI site compared to the 4-6 present in the 227 bp 
product generated during routine PCR-RFLP analysis (Fig. 1B).  Each genotype gave 
a specific combination of HhaI fragment sizes following digestion and separation on 
20% Tris-buffered EDTA-polyacrylamide gels: apoE4, 85 and 33 bp; apoE3, 118 bp; 
and apoE4/E3, 118, 85 and 33 bp.  The sense primer from the routine PCR-RFLP 
analysis,  and  antisense  primer  from  the  locus-specific  analysis,  were  used  for 
automatedDNA sequencing of purified PCR products.
‘Spiking’ experiments
Two  different  experiments  were  designed  to  evaluate  if the chimeraplast, whether intact or degraded, could function as a primer or template in the PCR-based analyses.  
In the first study, increasing amounts of intact chimeraplast (3 pg-300 ng) were added 
directly to the PCR mix, which also contained 100 ng of CHO-E4 DNA.  In the 
second study, CHO-K1 cells were transfected with different amounts of apoE4-to-E3 
chimeraplast (600-1000 nM) and 24 h-48 h later DNA was extracted and mixed 1:1 
with CHO-E4 or E4-lymphocyte DNA; 100 ng of this total DNA was used in the 
standard 25 µl PCR reaction.  PCR-RFLP analyses were performed as outlined above.
Results
Short-term  conversion  of  APOE4  to  APOE3 in  recombinant  CHO  cells  and 
human lymphocytes
 Subconfluent CHO-E4 cells were treated with a 68-mer apoE4-to-E3 chimeraplast 
(Fig.ure 1a), at a range of concentrations and amine to phosphate (PEI:RNA/DNA 
oligonucleotide) molar ratios.  A clear conversion was seen at each concentration 
tested  using  routine  PCR-RFLP17 (Hixson  and  Vernier,  1990)  (Fig.ure  1Bb), 
although  the  most  efficient  conversion  was  achieved  at  800  nM  and  an  8:1 
amine:phosphate molar ratio (Fig.ure 2Aa).  These conversions were confirmed by 
direct sequencing (Figs.ures 2Bb-2Ee), while the same apoE4-to-E3 chimeraplast 
was used as a negative control and had no effect on CHO-E2 cells (Fig.ure 2Aa).  
The  APOE4 gene  was  also  targeted  in  cultured  lymphocytes  from  a 
homozygous ε4/ε4 patient for 16 h with increasing concentrations (400-1000 nM) of 
PEI:chimeraplast at amine:phosphate molar ratios of 5:1-7:1.  A clear conversion of 
APOE4 to APOE3 was seen at 800 and 1000 nM, whereas the genotype of E2 
lymphocytes, used as a negative control, was unchanged (Fig.ure 3Aa).  A 7:1 ratio 
of PEI to oligonucleotide and 800 nM of chimeraplast gave the highest conversion 
and  this  was  confirmed  by  direct  sequencing  (Figs.ures 3Bb-3eE).    However, 
analyses of the conversions by PCR-RFLP for both cell types were complicated by 
the appearance of an additional ‘unexpected’ band at 83 bp.  This ‘unexpected’ band 
may reflect partial digestion, and its frequent appearance has been noted previously 
during routinewhen genotyping of apoE4/E3 or apoE4/E4 patients (Wu et al., 2000)
18.    To  circumvent  this  problem  a  new  locus-specific  PCR-RFLP  was  devised (Fig.ure 1cC) and used in selected studies.
APOE4 to APOE3 gene conversion by chimeraplasty is not artefactual
Two methods were employed to investigate whether APOE4 to APOE3 conversions 
could be attributed to PCR artefacts.  Firstly, increasing amounts (1 pg-300 ng) of 
intact  apoE4-to-E3  chimeraplast  were  mixed  into  a  standard  PCR-RFLP  reaction 
containing 100 ng of DNA extracted from CHO-E4 cells.  This procedure did not give 
rise  to  a  PCR-generated  artefact  as  no  diagnostic  apoE3  band  (91  bp)  appeared 
(Fig.ure 4Aa).  Secondly, CHO-K1 cells were transfected with varying amounts of 
apoE4-to-E3 chimeraplast (600-1000 nM); 48 h later DNA was extracted from the 
cells  and  mixed  1:1  with  CHO-E4  or  E4-lymphocyte  DNA.  Again,  using  locus-
specific PCR-RFLP analysis,  there was no evidence of any artefactually-produced 
band,  this  time  using  locus-specific  PCR-RFLP  analysis,  implying  that  any 
intracellular degradation products do not act as PCR templates or primers (Fig.ure
4Bb).  
Unsuccessful long-term apoE4 to apoE3 conversion in CHO-E4 cells 
CHO-E4  cells  were  transfected  with  800  nM  apoE4-to-E3  chimeraplast  at  an 
amine:phosphate ratio of 8:1 at an amine:phosphate ratio of 8:1, which gave optimal 
conversion (Fig.ure 2Aa), and maintained in culture for 10 days, passaging every other 
day.  The cells were then cloned by limiting dilution and ring isolation, expanded and 
their cellular DNA extracted for analysis by locus-specific PCR-RFLP and for some 
clones by direct sequencing.  No conversion to apoE3 was detectable by PCR-RFLP 
analysis for any of the clones (Fig.ure 5Aa).  Direct DNA sequencing confirmed the 
genotypes were unchanged and provided no evidence that any of the individual clones 
analsysed might have been converted to the apoE3 genotype (Fig.ure 5B6b). 
Discussion
Chimeraplast-directed  substitution  of  single  bases  within  a  gene  is  a  powerful 
technology with enormous potential.  Importantly, like other tissues and organs, the 
brain as well as liver and other organs is amenable to gene transfer19(Shi et al., 2001).  
Conversion of apoE4-expressing cells to apoE3 is an intriguing possibility; as the ε4 
allele  is  strongly  associated  with  AD  and  a  variety  of  other  neurodegenerative disorders (Gasparini et al., 1998; Saunders, 2000)6,7 and also , as well as predictsing
poor prognosis in traumatic brain injury (Kay et al., 2003)720,19.  Therefore, targeting 
the APOE4 gene in brains of patients with AD to express apoE3 (or apoE2) could 
prove beneficial, and an attractive therapeutic possibility, which could be explored 
first in transgenic mice expressing human apoE4 (Xu et al., 1996; Gong et al., 2002)
210,212..  
Here, in short-term preliminary experiments, we targeted recombinant CHO 
cells expressing apoE4 with an 68-mer apoE4-to-E3 chimeraplast of standard design
(Tagalakis et al., 2001)16 68-mer.  Evidence for a successful conversion of the APOE4
gene was obtained both by PCR-RFLP analysis (91, 72 and 48 bp bands) and by direct 
sequencing  of  the  PCR  product,  which  showed  an  apoE4/E3  genotype  for  treated 
cells.  Genomic APOE4 was also targeted in cultured transformed lymphocytes from a 
homozygous  ε4/ε4  patient  using  the  same  chimeraplast;  clear  conversion  to  the 
apoE4/E3 genotype was seen by PCR-RFLP and confirmed by sequencing.  These 
conversions did not occur through a PCR artefact.  The diagnostic band did not appear 
in spiking experiments when the chimeraplast was added directly to the PCR mix or 
when  DNA  extracted from transfected CHO-K1 cells, which potentially contained 
degraded chimeraplast fragments, was used in the PCR reaction.  Therefore, we reject 
the  possibility  that  intact  chimeraplasts,  or  chimeraplast  degradation  products 
generated intracellularly, can act as primers and/or template, as suggested by some 
researchers (Thomas et al., 1997; Zhang et al., 1998)232.
When CHO-E4 cells were cultured for 10 days after chimeraplasty and then 
cloned, no conversion was detected in over 90 clones analysed by locus-specifc PCR-
RFLP.  This longer term study implied that the conversion to APOE3 was not stable, 
in contrast with our previous finding for APOE2 to APOE3 gene repairs (Tagalakis et 
al., 2001)16 or the reports of other researchers targeting different genes13-15 (Kren et 
al., 1998; Alexeev et al., 2000; Bertoni and Rando, 2002).  One explanation for this 
apparent  instability  might  be  an  irreversible  cytotoxic  action  of  the  transfection 
complex  on  the  CHO-E4  cells,  perhaps  making  them  vulnerable  to  apoptosis.  
Consistent  with  this  possibilityInterestingly,  we  found  that  the  concentration  of 
apoE4-to-apoE3 chimeraplast needed for successful conversion was high (800 or 1000 
nM;  Figures  2  and  3),  whereas  our  previous  conversions  with  apoE2-to-apoE3 
chimeraplasts were accomplished efficiently with lower amounts (200 or 400 nM)(Tagalakis et al., 2001)16.  Thus, a two-fold or greater increase in chimeraplast, or 
perhaps more significantly its carrier PEI, which has potential cyotoxicity (Fischer et 
al., 1999; Olsen et al., 2003)243 [xx], might have contributed to the instability of the 
repair.    An  alternative,  though  less  likely  explanation,  is  that  the  switch  from  an 
apoE4 to apoE3 phenotype promoted cell death, perhaps because of a difference in 
intracellular trafficking of the two apoE isoforms (Strittmatter et al., 2002; DeKroon 
and Armati, 2003)8,254.  However, it should also be noted that our cloning analysis 
may have missed low-level stable conversions of ≤1 %, which have previously been 
reported  in  mammalian  cells  using  sensitive  reporter  gene  assays  (Thorpe  et  al., 
2002a; Tran et al., 2003; Nickerson and Colledge, 2003)265-287.
Our  current  failure  to  achieve  detectable  long-term  correction  of  the 
dysfunctional APOE4 gene mirrors several recent reports highlighting failure or poor 
reproducibility when targeting other genes (Van der Steege et al., 2001; Albuquerque-
Silva et al., 2001; Taubes, 2002)298-310.  This is perhaps not entirely unexpected as the 
technology  is  relatively  new  and  evolving  with  many  factors  yet  to  be  optimized
(Graham et al., 2001; Yoon et al., 2002)321,332.  One problem may be the quality of the 
chimeraplast  itself;  the  reagents  are  long  molecules  which  tend  to  self-associate 
during synthesis, both features that would promote formation of N-1 failure fragments 
and other impurities (Manzano et al., 2003)343.  Indeed, the higher concentration of 
chimeraplast needed to convert APOE4 to APOE3, compared to APOE2 to APOE3
conversions (Tagalakis et al., 2001)16, may simply reflect a lower quality reagent.  An 
additional problem, in some ways common to general gene therapy strategies, is to 
ensure efficient delivery to the cell nucleus (and in vivo to the target organ itself), 
avoiding  reagent  degradation  or  cytotoxic  effects  (Ogris  and  Wagner,  2002)354.  
Finally,  more  work  is  needed  into  basic  mechanisms  by  which  cells  accomplish 
mismatch repair, an area about which we remain largely ignorant.  Stimulation of 
repair by synchronizing cell cycles to the S-phase (Majumdar et al., 2003)364 or by 
increasing expression of RAD51 (Thorpe et al., 2002a,b; Liu et al., 2001)265,376,387
appear useful starting points for improving efficiency.  Given the enormous potential 
of oligonucleotide-directed gene repair, it is hoped that such developments will allow 
progress to wards the final goal ― a viable treatment for disease caused by ing point 
mutations, including neurodegenerative disorders associated with the ε4 allele. Materials and methods
Cell culture
The cloned recombinant CHO cell lines expressing human apoE4 that was used in 
these studies was produced by the methodas previously described for CHO-E2 cells16.  
Thesey  recombinant  cells  were  cultured in  Iscove’s  modified  Dulbecco’s  medium 
with  10%  dialyzed  FBS  (fetal  bovine  serum;  Sigma),  supplemented  with  2  mM 
glutaMAX and 1% non-essential aminoacids (Life Technologies).  Lymphocytes were 
isolated from the heparinized-blood of a patient homozygous for the ε4 allele and 
immortalized  with  Epstein-Barr  virus398.    These  transformed  cells  were  grown  as 
suspension cultures in RPMI 1640 medium, supplemented with 10% FBS and 2 mM 
L-glutamine. 
Chimeraplasty and transfections
The RNA/DNA oligonucleotides were synthesized commercially by MWG-Biotech 
(Ebersberg, Germany) to designs dictated by the target DNA (Figure 1a).  One strand 
of the self-associating duplex, termed the 'targeting strand'3409, had ten complementary 
2'-O-methyl  RNA  residues  flanking  each side  of  the  5-base-DNA  stretch.    The 
protected RNA bases resist RNase H-mediated degradation, while four T-residues in 
each  loop  and  a  5  bp  GC  clamp  ensured  that  they  self-associated  into  a  double-
hairpin.  The other 'correcting strand' was all DNA and, except for the intended base 
mismatch, was complementary to the genomic DNA target.  Cells were seeded into6-
well plates (2 × 105 cells/well) 24 h prior to transfections.  Chimeraplasts (400-1000 
nM)  were  pre-incubated  for  10  min  with  linear  22-kDa  polyethyleneimine  (PEI) 
(ExGen 500; TCS Biologicals Ltd.), at different amine: phosphate molar ratios (5:1 to 
9:1) and with the addition of 150 mM NaCl.  The complexes (50 µl) were then added
to each well of cells growing in 0.5 ml of serum-containing medium.  After 4-6 h, 
monolayers were washed with phosphate-buffered saline (PBS) and incubated with 2 
ml of fresh medium for 48 h prior to harvesting the cells and extracting the genomic 
DNA.  In the long-term experiments, we continued to passage and culture cells for 10 
days before isolating clones by limiting dilution and by ring cloning. 
ApoE genotyping and DNA sequencing 
Genomic DNA (DNeasy kit; Qiagen) was extracted from cells for routine PCR-RFLP 
genotyping17, amplifying a 227 bp product by 36 cycles (94 °C for 30 sec and 68 °C for 30 sec) with the primer pair, 5’-TCCAAGGAGCTGCAGGCGGCGCA-3’ (sense) 
and  5’-ACAGAATTCGCCCCGGCCTGGTACACTGCCA-3’  (antisense)  and 
separating the HhaI digested fragments on 20% Tris-buffered EDTA-polyacrylamide 
gels (Invitrogen).  Each genotype gave a specific combination of HhaI fragment sizes: 
apoE2, 91 and 83 bp; apoE3, 91 and 48 bp; and apoE4, 72 and 48 bp (Figure 1b).  A 
locus-specific PCR was also devised to avoid the appearance of ambiguous fragments, 
which  often  result  from  routinestandard  PCR-RFLP  analyses  involving  the  apoE4 
genotype18.  This involved 36 cycles of PCR (94 °C for 30 sec and 68 °C for 30 sec) 
with  the  primer  pair,  5’-AGGCCCGGCTGGGCGTGG-3’  (sense)  and  5’-
TGGGAGGCGAGACGCACCCG-3’  (antisense)  and  was  designed  to  amplify  a 
region around the E4/E3 locus, whilst abolishing two HhaI restriction sites.  The final 
118 bp product contains only one HhaI site compared to the 4-6 present in the 227 bp 
product generated during routine PCR-RFLP analysis (Figure 1b).  Each genotype 
gave a specific combination of HhaI fragment sizes following digestion and separation 
on 20% Tris-buffered EDTA-polyacrylamide gels: apoE4, 85 and 33 bp; apoE3, 118 
bp; and apoE4/E3, 118, 85 and 33 bp.  The sense primers for the routinestandard or 
locus-specific  PCR-RFLP  analyses  were  used  for  automated DNA  sequencing  of 
purified PCR products.
‘Spiking’ experiments
Two  different  experiments  were  designed  to  evaluate  ifwhether  the  chimeraplast, 
whether intact or degraded, could function as a primer or template in the PCR-based 
analyses.  In the first study, increasing amounts of intact chimeraplast (3 pg-300 ng) 
were added directly to the PCR mix, which also contained 100 ng of CHO-E4 DNA.  
In the second study, CHO-K1 cells were transfected with different amounts of apoE4-
to-E3 chimeraplast (600-1000 nM) and 24 h-48 h later DNA was extracted and mixed 
1:1 with CHO-E4 or E4-lymphocyte DNA; 100 ng of this total DNA was used in the 
standard 25 µl PCR reaction.  PCR-RFLP analyses were performed as outlined above.
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FIGURE LEGENDS
Figure 1  Chimeraplast design and apoE genotype analysis by PCR-RFLP. (a) The sequence 
of  the apoE4-to-E3 chimeraplast, which is internally matched16, is shown with the DNA 
residues in capital letters and the 2’-O-methylated RNA bases in lowercase.  The all-DNA 
‘correcting strand’ is underlined with the central mutating residue double-underlined, while 
the DNA mutator region of the ‘targeting strand’ is shown in bold.  (b) Routine genotyping17
was performed by amplifying a 227 bp PCR product from exon IV and restriction isotyping 
with HhaI.  Cleavage sites for HhaI are shown by arrows and are given for apoE2, E3 and E4 
amplified sequences; codons 112 and 158 are depicted as filled boxes.  (c)  Locus-specific 
PCR-RFLP  was  introduced  to  avoid  ambiguities  arising  from  routine  genotyping.  E4/E3 
locus-specific primers were designed to amplify a smaller fragment, whilst abolishing two 
HhaI sites during the PCR reaction.  The complete sequence of the amplified 118 bp product, 
which encompasses the E4/E3 locus, is shown; the residues matching the PCR primers are in 
bold and the two C nucleotides which are modified during PCR to T are underlined.  The 
four nucleotides in bold (GCGC) between the primer pair denotes the only HhaI site now left 
in  the  PCR  product  with  the  underlined  cytosine  being  the  nucleotide  targeted  by 
chimeraplasty. 
Figure 2  Conversion of the apoE4 cDNA in stably-transfected recombinant CHO cells to 
apoE3 by chimeraplasty.  (a) Clear conversions of apoE4 to apoE3 cDNA (C→ T) were seen 
48 h after transfecting recombinant CHO-E4 cells with the 68-mer apoE4-to-E3 chimeraplast 
at 800 nM at increasing amine:phosphate (PEI:RNA/DNA oligonucleotide) molar ratios (6:1-
8:1),  as  judged  by  appearance  of  the  diagnostic  91  bp  band.    (b-e) Sequencing 
chromatograms of chimeraplast-treated CHO-E4 cells.  As expected, the untreated CHO-E4 
cells (b) had only a C at the respective codon (112) of the apoE cDNA (arrowed), whereas 
partial gene conversion was evident in CHO-E4 cells treated with 800 nM of chimeraplast, 
since the T expected for apoE3 was additionally present (c-e).  The highest conversion (e) was seen at an amine:phosphate molar ratio of 8:1 (e), whereas lower conversion efficiencies 
were observed at ratios of 6:1 (c) and 7:1 (d).
Figure 3  Converting genomic the APOE4 gene to APOE3 in human lymphocytes. (a) Clear 
conversions of the APOE4 gene to APOE3 (C→ T) wasere seen 48 h after transfecting EBV-
transformed  lymphocytes  from  a  patient  homozygous  for  the  ε4  allele  with  the  68-mer 
apoE4-to-E3  chimeraplast  using  increasing  oligonucleotide  concentrations  and  different 
amine:phosphate  molar  ratios,  as  judged  by  appearance  of  the  diagnostic  91  bp  band.  
Ladder,  10  bp  markers;    E2-control,  lymphocytes  from  an  ε2/2  patient  treated  with  the 
apoE4-to-E3  chimeraplast.    (b-e) Sequencing  chromatograms  of  chimeraplast-treated  E4-
lymphocytes.  Partial gene conversion was confirmed (b) by direct sequencing ofas the PCR 
product from treated E4-lymphocytes (800 nM, 6:1 amine:phosphate molar ratio), sincewhich 
had the T predicted for apoE3 was present as well as the C of apoE4.  The highest conversion 
(c) was seen at 800nM and a 7:1 amine:phosphate molar ratio, while lower conversions were 
noted at 1000 nM and at 6:1 (d) or 7:1 (e) amine:phosphate molar ratios.
Figure 4  Chimeraplast-mediated conversion of E4 to E3 conversion is not artefactual. (a) 
Varying amounts (1 pg-300 ng) of intact apoE4-to-E3 chimeraplast were added to the routine 
PCR-RFLP reaction mix containing DNA extracted from untreated CHO-E4 cells.  This PCR 
reaction  did  not  produce  artefacts  as  no  diagnostic  band  (91  bp)  appeared.    Lad,  10  bp 
markers; Con, control unspiked CHO-E4 cells.  (b) Cultured CHO-K1 cells were transfected 
with increasing amounts of apoE4-to-E3 chimeraplast (600-1000 nM) and 48 h later DNA 
was extracted and mixed 1:1 with DNA from untreated CHO-E4 cells or E4-lymphocytes.  
Analysis by locus-specific PCR-RFLP failed to reveal a diagnostic apoE3 band (118 bp), 
implying  that  chimeraplast-degradation  products  did  not  generate  artefacts.    Lad,  10  bp 
markers.
Figure  5    Long-term  conversion  of  the  APOE4  gene  to  APOE3  was  not  successful  in 
recombinant  CHO-E4  cells.    (a)  CHO-E4  cells  were  transfected  optimally  with  800  nM 
apoE4-to-E3 chimeraplast at an 8:1 amine:phosphate molar ratio.  The cells were maintained 
in culture for 10 days, passaging several times, and then 93 clones isolated and expanded by 
limiting dilution and ring cloning.  Cellular DNA was isolated for analysis by PCR-RFLP 
and, in some cases, by direct sequencing; no conversion to apoE3 was detectable in any of 
the clones.  (a) Locus-specific PCR-RFLP analysis of 8 clones picked consecutively (clones 
9-16), which all show complete absence of the diagnostic 118 bp.  Con, control untreated 
CHO-E4 cells.  (b) Sequence chromatogram of the 118 bp PCR product from a representative 
clone (clone 15).  There was no evidence for conversion of the G in apoE4 (circled) to the A 
expected for apoE3. A
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Fig. 1  Chimeraplast design and apoE genotype analysis by PCR-RFLP. (A) The sequence of 
the apoE4-to-E3 chimeraplast, which is internally matched (Tagalakis et al., 2001), is shown 
with the DNA residues in capital letters and the 2’-O-methylated RNA bases in lowercase.  
The  all-DNA  ‘correcting  strand’  is  underlined  with  the  central  mutating  residue  double-
underlined, while the DNA mutator region of the ‘targeting strand’ is shown in bold.  (B) 
Routine  genotyping  (Hixson  et  al.,  1990)  was  performed  by  amplifying  a  227  bp  PCR 
product  from  exon  IV  and  restriction  isotyping  with  HhaI.    Cleavage sites for HhaI are 
shown by arrows and are given for apoE2, E3 and E4 amplified sequences; codons 112 and 
158 are depicted as filled boxes.  (C)  Locus-specific PCR-RFLP was introduced to avoid 
ambiguities arising from routine genotyping. E4/E3 locus-specific primers were designed to 
amplify a smaller fragment, whilst abolishing two HhaI sites during the PCR reaction.  The 
complete sequence of the 118 bp, encompassing the E4/E3 locus, which was targeted by PCR 
is shown; the residues matching the PCR primers are in bold and the two C nucleotides which are modified during PCR to T are underlined.  The four nucleotides in bold (GCGC) 
between the primer pair denotes the only HhaI site now left in the PCR product with the 
underlined cytosine being the nucleotide targeted by chimeraplasty.
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Figure 2Fig.  2    Conversion  of  the  apoE4  cDNA  in  stably-transfected  recombinant  CHO  cells  to 
apoE3 by chimeraplasty.  (A) Clear conversions of apoE4 to apoE3 cDNA (C→ T) were seen 
48 h after transfecting recombinant CHO-E4 cells with the 68-mer apoE4-to-E3 chimeraplast 
at 800 nM at increasing amine:phosphate (PEI:RNA/DNA oligonucleotide) molar ratios (6:1-
8:1),  as  judged  by  appearance  of  the  diagnostic  91  bp  band.    (B-E) Sequencing 
chromatograms of chimeraplast-treated CHO-E4 cells.  As expected, the untreated CHO-E4 
cells (B) had only a C at the respective codon (112) of the apoE cDNA (arrowed), whereas 
partial gene conversion was evident in CHO-E4 cells treated with 800 nM of chimeraplast, 
since the T expected for apoE3 was additionally present (C-E).  The highest conversion (E) 
was seen at an amine:phosphate molar ratio of 8:1 (E), whereas lower conversion efficiencies 
were observed at ratios of 6:1 (C) and 7:1 (D).A
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Figure 3Fig. 3  Converting genomic APOE4 to APOE3 in human lymphocytes. (A) Clear conversion 
of the APOE4 gene to APOE3 (C→ T) was seen 48 h after transfecting EBV-transformed 
lymphocytes  from  a  patient  homozygous  for  the  ε4  allele  with  the  68-mer  apoE4-to-E3 
chimeraplast using increasing oligonucleotide concentrations and different amine:phosphate 
molar ratios, as judged by appearance of the diagnostic 91 bp band.  Ladder, 10 bp markers;  
E2-control, lymphocytes from an ε2/2 patient treated with the apoE4-to-E3 chimeraplast.  (B-
E) Sequencing  chromatograms  of  chimeraplast-treated  E4-lymphocytes.    Partial  gene 
conversion was confirmed (B) by direct sequencing of the PCR product from treated E4-
lymphocytes (800 nM, 6:1 amine:phosphate molar ratio), since the T predicted for apoE3 was 
present as well as the C of apoE4.  The highest conversion (C) was seen at 800nM and a 7:1 
amine:phosphate molar ratio, while lower conversions were noted at 1000 nM and at 6:1 (D) 
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Chimeraplast (nM) Fig. 4  Chimeraplast-mediated conversion of E4 to E3 conversion is not artefactual. (A) 
Varying amounts (1 pg-300 ng) of intact apoE4-to-E3 chimeraplast were added to the routine 
PCR-RFLP reaction mix containing DNA extracted from untreated CHO-E4 cells.  This PCR 
reaction  did  not  produce  artefacts  as  no  diagnostic  band  (91  bp)  appeared.    Lad,  10  bp 
markers; Con, control unspiked CHO-E4 cells.  (B) Cultured CHO-K1 cells were transfected 
with increasing amounts of apoE4-to-E3 chimeraplast (600-1000 nM) and 48 h later DNA 
was extracted and mixed 1:1 with DNA from untreated CHO-E4 cells or E4-lymphocytes.  
Analysis by locus-specific PCR-RFLP failed to reveal a diagnostic apoE3 band (118 bp), 
implying  that  chimeraplast-degradation  products  did  not  generate  artefacts.    Lad,  10  bp 
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Clone 15Fig.  5    Long-term  conversion  of  the  APOE4  gene  to  APOE3  was  not  successful  in 
recombinant CHO-E4 cells.  (A) CHO-E4 cells were transfected optimally with 800 nM 
apoE4-to-E3 chimeraplast at an 8:1 amine:phosphate molar ratio.  The cells were maintained 
in culture for 10 days, passaging several times, and then 93 clones isolated and expanded by 
limiting dilution and ring cloning.  Cellular DNA was isolated for analysis by PCR-RFLP 
and, in some cases, by direct sequencing; no conversion to apoE3 was detectable in any of 
the clones.  (A) Locus-specific PCR-RFLP analysis of 8 clones picked consecutively (clones 
9-16), which all show complete absence of the diagnostic 118 bp.  Con, control untreated 
CHO-E4  cells.    (B)  Sequence  chromatogram  of  the  118  bp  PCR  product  from  a 
representative clone (clone 15).  There was no evidence for conversion of the G in apoE4 
(circled) to the A expected for apoE3. 